PUBLISHER: DataM Intelligence | PRODUCT CODE: 1316287
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1316287
The global left ventricular assist device (LVAD) market reached US$ 1.4 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 2.3 billion by 2030. The global left ventricular assist device (LVAD) market is expected to exhibit a CAGR of 7.2% during the forecast period (2023-2030).
Left Ventricular Assist Devices (VAD) are mechanical circulatory support strategies planted in heart failure individuals with intense manifestation and operation by pumping blood from the chambers of the heart to the entire body. The increase in the number of heart failures, rising type launches, advancements, and increasing market developments are among the factors expected to boost the global left ventricular assist device (LVAD) market growth in the forecast period.
The increasing cases of heart failure are expected to boost the global left ventricle assist device market growth in the forecast period. Heart failure is extremely typical. Although improvement is created in the treatment of multiple states of heart conditions, heart failure is a growing concern globally. For instnace, according to the Heart Failure Society of America, the current assessments are that nearly 6.5 million Americans over the age of 20 suffer heart failure. One significant investigation assessment indicates that there are over 960,000 fresh heart failure patients yearly. Not only is heart failure a significant issue impacting a considerable number of individuals, but heart failure is even a prominent killer. Heart failure directly accounts for approximately 8.5% of all heart condition deaths in the United States. And, to some assessments, heart failure contributes to about 36% of all cardiovascular disease deaths.
Increasing research initiatives are estimated to boost the global For instance, in the foremost action in ensuring FDA authorization, Israel-based device maker Magenta Medical is initiating a premature feasibility investigation with its Elevate percutaneous Left Ventricular Assist Device (pLVAD) for high-risk percutaneous coronary intervention (HR-PCI).
The high cost of LVAD implantation is estimated to hamper the global left ventricular assist device market growth in the forecast period. For instance, according to the NIH, the mean cost of LVAD implantation was USD 175,420. However, LVADs proven heart failure patients improved quality of life but substantially increased lifetime costs because of frequent readmissions and costly follow-up care.
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
The Russia-Ukraine conflict is thought to hold a moderate influence on the global left ventricular assist device (LVAD) market, as there is a low incidence of heart failure and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of raw materials are expected to slightly impact the global Left Ventricular Assist Device (LVAD) market growth in the forecast period.
The global left ventricular assist device (LVAD) market is segmented based on type, pump type, application, end-user, and region.
Owing to the increase in the procedures of implantable LVAD, implantable LVAD is estimated to hold around 23.9% of the global market share by 2030. For instnace, in July 2022, a team from Emory's Heart and Vascular Center conducted its 500th continuous flow, durable left ventricular assist device (LVAD) implantation, additionally establishing Emory Healthcare's position as a national leader in the life-saving procedure.
Owing to the key player's efforts in the Europe region, the region is estimated to hold around 27.1% of the global market share. For instance, UK-based Calon Cardio-Technology Ltd. seeks to obtain the CE Mark for its MiniVAD in earlier 2024, by which period a US FDA Early Feasibility Study is expected to have been concluded. The corporation pursues to boost investments of almost USD 47 million (£34 million) to USD 60 million (£43 million) to finance its clinical investigations of the MiniVAD in the US and Europe from 2020 to 2023.
The major global players in the Left Ventricular Assist Device (LVAD) market include: CorWave, Apaxis Inc., Sunshine Heart, HeartWare International (Medtronic), Sun Medical Technology Research, Abiomed, Terumo Corporation, Evaheart, Jarvik Heart, and Thoratec (Abbott), among others.
The global left ventricular assist device (LVAD) market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Australia
LIST NOT EXHAUSTIVE